AbbVie strikes $1.19 billion collaboration deal with Halozyme, Ferring Pharmaceuticals expands into Russian market & more – 5 GI/endoscopy company key notes

Here are five recent news updates on gastroenterology and endoscopy companies.

AbbVie and Halozyme Therapeutics reached a global collaboration agreement that could be worth $1.19 billion, according to a report by The Wall Street Journal

Ferring Pharmaceuticals awarded an agreement with Russian pharmaceutical company NovaMedica, which allows NovaMedica to commercialize a number of Ferring's inflammatory bowel disease products in the Russian market.

Medigus was awarded an additional supply order of its micro ScoutCam technology from the National Aeronautics and Space Administration. The technology will be used in NASA's Robotic Refueling Mission.

Synthetics Biologics added Klaus Gottlieb, MD, FACG, to its team as vice president of clinical and regulatory affairs. Dr. Gottlieb will provide further leadership support as Synthetic Biologics moves forward with Phase 2 clinical trials for its irritable bowel syndrome and Clostridium difficile products.

Valeant Pharmaceuticals received FDA approval for its IBS-D drug Xifaxan, according to a Triangle Business Journal report.

If you have a question, issue or note to suggest on a GI/endoscopy company please contact Carrie Pallardy at

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Whitepapers

Featured Podcast